تاریخچه درآمد، سود و جریان نقد از صورتهای مالی رسمی.
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally.
نمودارهای تعاملی و صورتهای مالی کامل ← مدل ارزشگذاری (DCF) ←
| صورت سود و زیان | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| مجموع درآمد | $3.4B | $3.2B | $2.9B | $2.4B | $2.1B | $1.8B | $1.9B | $1.7B | $1.5B | $1.3B | $1.1B | $890M | $749M | $548M | $501M | $441M | $376M | $325M | $296M | $122M | $84M |
| سود ناخالص | $2.6B | $2.5B | $2.3B | $1.9B | $1.6B | $1.4B | $1.3B | $1.3B | $1.2B | $1.1B | $907M | $738M | $627M | $460M | $409M | $357M | $306M | $259M | $244M | $103M | $75M |
| حاشیه سود ناخالص % | 75.5% | 77.1% | 79.7% | 78.0% | 76.0% | 74.5% | 71.8% | 78.9% | 78.9% | 81.6% | 81.2% | 82.9% | 83.7% | 83.9% | 81.7% | 81.0% | 81.3% | 79.7% | 82.3% | 84.9% | 89.6% |
| سود عملیاتی (EBIT) | $273M | $533M | $484M | $186M | $161M | ($82M) | ($43M) | ($100M) | ($124M) | ($15M) | ($803M) | ($111M) | ($93M) | ($156M) | ($110M) | ($34M) | $1M | $16M | $40M | ($57M) | ($25M) |
| حاشیه سود عملیاتی % | 8.0% | 16.6% | 17.0% | 7.7% | 7.7% | -4.5% | -2.3% | -5.9% | -8.3% | -1.1% | -71.9% | -12.4% | -12.4% | -28.4% | -22.0% | -7.7% | 0.1% | 5.1% | 13.4% | -47.1% | -29.3% |
| سود خالص | $73M | $349M | $427M | $168M | $142M | ($64M) | $854M | ($24M) | ($77M) | ($117M) | ($630M) | ($172M) | ($134M) | ($176M) | ($114M) | ($54M) | $206M | $0M | $31M | ($16M) | ($29M) |
| حاشیه سود خالص % | 2.1% | 10.8% | 15.0% | 6.9% | 6.8% | -3.5% | 45.9% | -1.4% | -5.2% | -8.9% | -56.4% | -19.3% | -17.9% | -32.1% | -22.8% | -12.2% | 54.7% | -0.1% | 10.4% | -13.0% | -33.9% |
| EBITDA | — | $573M | $651M | $307M | $265M | $47M | $84M | $32M | ($3M) | $91M | ($698M) | ($73M) | ($46M) | ($131M) | ($67M) | $0M | $17M | $36M | $67M | ($53M) | ($15M) |
| سود هر سهم (EPS) | $0.36 | $1.77 | $2.17 | $0.87 | $0.75 | $-0.35 | $4.46 | $-0.13 | $-0.44 | $-0.67 | $-3.79 | $-1.07 | $-0.92 | $-1.28 | $-0.95 | $-0.48 | $1.64 | $-0.00 | $0.30 | $-0.16 | $-0.34 |
| سهام منتشرشده (میلیون) | — | 197M | 197M | 192M | 189M | 183M | 192M | 179M | 177M | 174M | 166M | 160M | 146M | 138M | 120M | 112M | 126M | 100M | 104M | 96M | 85M |
منبع: گزارشهای عمومی شرکت (SEC). پیش از اتکا به هر رقم، آن را در SEC EDGAR بررسی کنید.
ترازنامهها، جریانهای نقدی، دادههای فصلی و نسبتهای مالی کامل در نمایشگر تعاملی BMRN در دسترس است. /companies/us/BMRN
اطلاعات این وبسایت صرفاً برای اهداف آموزشی و اطلاعرسانی است و توصیه سرمایهگذاری نیست. هیچ هدف قیمتی یا توصیهای منتشر نمیشود.
About TickerBase · Data methodology & sources · Privacy · Terms